Description
LLL12 is a potent STAT3 inhibitor. LLL12 inhibits colony formation and cell migration and works synergistically with doxorubicin and gemcitabine. LLL12 demonstrated a potent inhibitory activity on breast and glioblastoma tumor growth in a mouse xenograft model. LLL12 may be a potential therapeutic agent for human cancer cells expressing constitutive STAT3 signaling.
Uses
LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth[1].
References
[1] Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin and paclitaxelmediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232. DOI:
10.3892/or.2020.7667[2] Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26. DOI:
10.1007/s10637-011-9645-1
